Table 4.

AMP-502 clinical trial differential responses^a.

	Percentage change (n)
Parameter	Rintatolimod	Placebo	p-Value
KPS	+20 (41)	0 (43)	<0.001 (mean)/0.023 (median)b
Cognitive deficit	+27.3 (40)	+14.5 (43)	0.05c
ADL status	+23.1 (41)	+ 14.1 (43)	0.034c
Exercise duration	+10.3 (37)	+ 2.1 (39)	0.007d
Exercise work	+11.8 (37)	+5.8 (39)	0.011e

^aModified from [24] (Clinical Infectious Diseases/Oxford University Press).

^bMedian change (Week 24 vs. baseline) by Mann–Whitney test.

^cAn increased score quantifies a reduction in perceived deficit.

^dANCOVA with baseline as covariate.

^eANCOVA of log-transformed data with baseline as covariate.